Pulse Biosciences, Inc.

PLSE Nasdaq SEC CIK 1625101
Follow Pulse Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $395K +359.3% vs same quarter last year
Net income −$23.1M −18.9% vs same quarter last year
EPS, diluted −$0.32 −10.3% vs same quarter last year
Operating cash flow −$15.3M −17.1% vs same quarter last year
Revenue by quarter
$0
$0
$0
$86K
$264K
$401K
$434K
$395K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$80M−$60M−$40M−$20M$0$20MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$350K−$72.8M
FY24$0−$53.6M
FY23$0−$42.2M
FY22$700K−$58.5M
FY21$1.4M−$63.7M
FY20$0−$49.9M
FY19-−$47M
FY18-−$37.5M
FY17-−$25.6M
FY16-−$9.5M
FY15-−$2.8M
FY14--
MarginsShare of revenue
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−21982.6%−20794.6%
FY24--
FY23--
FY22−8293.9%−8357.9%
FY21−4443.9%−4489.4%
FY20--
FY19--
FY18--
FY17--
FY16--
FY15--
FY14--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$54.4M
FY24−$36.5M
FY23−$33.2M
FY22−$47.4M
FY21−$54.5M
FY20−$35.8M
FY19−$34.8M
FY18−$24.2M
FY17−$13.6M
FY16−$8.1M
FY15−$3.4M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Pulse Biosciences
  • Healthcare median
−30000%−20000%−10000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearPulse BiosciencesHealthcare median
FY25−20794.6%−30.6%
FY24-−47%
FY23-−58%
FY22−8357.9%−80.4%
FY21−4489.4%−71.9%
FY20-−62.2%
FY19-−46.3%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−38.4%
FY14-−35.5%